



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 MARCH 2017**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 31-03-17 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 31-03-16 RM'000	CURRENT YEAR TO DATE 31-03-17 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 31-03-16 RM'000
Revenue	123,306	79,470	123,306	79,470
Cost of Sales	(78,704)	(43,213)	(78,704)	(43,213)
Gross Profit	44,602	36,257	44,602	36,257
Other operating income	101	128	101	128
Distribution costs	(17,765)	(15,447)	(17,765)	(15,447)
Administration expenses	(13,651)	(10,250)	(13,651)	(10,250)
Other operating expenses	(567)	(497)	(567)	(497)
Profit from operations	12,720	10,191	12,720	10,191
Finance income	715	1,222	715	1,222
Finance costs	(1,313)	(1,472)	(1,313)	(1,472)
Profit before taxation	12,122	9,941	12,122	9,941
Taxation	(2,558)	(2,113)	(2,558)	(2,113)
Profit after tax for the period	9,564	7,828	9,564	7,828
Other comprehensive income				
Foreign currency translation differences for foreign operations		15		15
Total other comprehensive income for the period	9,564	7,843	9,564	7,843
Profit attributable to:				
Shareholders of the Company	9,564	7,843	9,564	7,843
Minority interest	-	-	-	-
	9,564	7,843	9,564	7,843
Total comprehensive income attributable to:				
Shareholders of the Company	9,564	7,843	9,564	7,843
Minority interest	-	-	-	-
	9,564	7,843	9,564	7,843
Earnings per share (sen)				
Basic (based on weighted average)	3.43	2.81	3.43	2.81
Diluted (based on weighted average)	3.43	2.81	3.43	2.81

- The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2016 and the accompanying explanatory notes attached to the interim financial statements.

**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2017**

	AS AT 31/3/2017 RM'000	AS AT 31/12/2016 RM'000
ASSETS		
Property, Plant and Equipment	286,952	276,241
Intangible assets	13,275	12,727
Deferred Tax Assets	6,778	6,313
Total non-current assets	307,005	295,281
Inventories	143,068	139,101
Trade & Other Receivables	117,205	94,378
Amount Due From Related Company	4,982	6,653
Current Tax Assets	9,646	10,236
Cash & Cash Equivalents	111,651	114,814
	386,552	365,182
Asset Held For Sale	1,000	1,000
Total current assets	387,552	366,182
Total Assets	694,557	661,463
EQUITY		
Share Capital	139,478	139,478
Reserves	194,074	193,772
Retained earnings	130,830	121,266
Total Equity	464,382	454,516
LIABILITIES		
Deferred Tax Liability	10,111	11,993
Borrowings	91,798	91,798
Total non-current liabilities	101,909	103,791
Trade & Other Payables	71,262	58,775
Amount due to related company	21,892	22,883
Borrowings	35,112	21,498
Taxation	-	-
Total current liabilities	128,266	103,156
Total Liabilities	230,175	206,947
Total Equity & Liabilities	694,557	661,463
	-	-
Net assets per share (RM)	1.66	1.63

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2016 and the accompanying explanatory notes attached to the interim financial statements.)